Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- loncastuximab tesirine
- Photofrin (porfimer)
Interactions between your drugs
porfimer loncastuximab tesirine
Applies to: Photofrin (porfimer), loncastuximab tesirine
Using porfimer together with loncastuximab tesirine may increase the risk of a photosensitivity reaction (e.G., redness, swelling, itching, burning sensation, feeling hot, and/or blisters), following exposure to sunlight or bright indoor lights such as examination, dental or operating room lamps; floodlights; halogen lights; and unshaded light bulbs at close proximity. It is recommended that loncastuximab tesirine be avoided for at least 30 days following therapy with porfimer, and until a test for residual photosensitivity shows no photosensitivity reaction within 24 hours. In some cases, it might be necessary to avoid photosensitizing medications for 90 days or longer, although it may not be feasible to interrupt some treatments for that long, especially if they are medically necessary. Exposing your skin to normal indoor lighting is helpful as it will help your body get rid of porfimer more quickly, so you do not need to stay inside in the dark. Check with your doctor to see if you should temporarily withhold any of your medications after taking porfimer or if you have any other questions. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Revlimid
Revlimid is used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma and ...
Deltasone
Deltasone is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Lenalidomide
Lenalidomide (Revlimid) is used to treat multiple myeloma, mantle cell lymphoma, follicular ...
Vincristine
Vincristine is used for acute lymphocytic leukemia, acute myeloid leukemia, anaplastic ...
Doxorubicin
Doxorubicin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Cyclophosphamide
Cyclophosphamide is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, brain ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.